Antifungal Treatment for Candida in Urine
Fluconazole is the first-line antifungal treatment for symptomatic Candida urinary tract infections, at a dosage of 200 mg (3 mg/kg) daily for 2 weeks for susceptible species. 1
Treatment Algorithm Based on Clinical Presentation
Asymptomatic Candiduria
- No treatment needed unless patient belongs to high-risk group 1
- High-risk groups requiring treatment:
- Neutropenic patients
- Low birth weight infants
- Patients undergoing urologic procedures
Symptomatic Candida Cystitis
First-line therapy: Fluconazole 200 mg daily for 2 weeks 1, 2
For fluconazole-resistant species:
Alternative therapy for resistant strains:
Candida Pyelonephritis
First-line therapy: Fluconazole 200-400 mg (3-6 mg/kg) daily for 2 weeks 1
For fluconazole-resistant species:
Fungus Balls
- Surgical intervention is strongly recommended in non-neonates 1
- Systemic therapy:
- Local therapy: Amphotericin B irrigation at 50 mg/L sterile water if access to collecting system is available 1
Important Clinical Considerations
Elimination of Predisposing Factors
- Remove indwelling catheters 1, 5
- Discontinue unnecessary antibiotics 5
- Correct urinary tract obstruction 1
- These interventions alone may resolve candiduria in up to 50% of cases 6
Antifungal Agents to Avoid
- Newer azoles (voriconazole, posaconazole) - poor urinary concentrations 1, 6
- Echinocandins (caspofungin, micafungin, anidulafungin) - poor urinary concentrations 1, 7, 6
- Exception: Some case reports show success with higher-dose micafungin (150 mg daily) in specific cases of resistant C. krusei 8
Duration of Treatment
- Continue treatment until symptoms resolve and urine cultures no longer yield Candida species 1, 4
- Standard duration is 2 weeks for most infections 1, 4
Monitoring
- Follow-up urine cultures to document clearance 4
- Monitor renal function when using amphotericin B formulations 4
- Assess for clinical improvement of symptoms 4
Pitfalls and Caveats
- Candiduria often represents colonization rather than infection, especially in catheterized patients 9
- Flucytosine monotherapy can lead to development of resistance; use with caution 1
- Amphotericin B bladder irrigation has high relapse rates and should be reserved for refractory cases 1
- Lipid formulations of amphotericin B do not achieve adequate urine concentrations for lower UTI treatment 1
- Echinocandins may be considered for renal parenchymal infections despite poor urinary concentrations, but clinical data is limited 1